Literature DB >> 17850485

To activate or not to activate: distinct strategies used by Helicobacter pylori and Francisella tularensis to modulate the NADPH oxidase and survive in human neutrophils.

Lee-Ann H Allen1, Ramona L McCaffrey.   

Abstract

Neutrophils accumulate rapidly at sites of infection, and the ability of these cells to phagocytose and kill microorganisms is an essential component of the innate immune response. Relatively few microbial pathogens are able to evade neutrophil killing. Herein, we describe the novel strategies used by Helicobacter pylori and Francisella tularensis to disrupt neutrophil function, with a focus on assembly and activation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850485     DOI: 10.1111/j.1600-065X.2007.00544.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  28 in total

1.  Hematopoietic MyD88 and IL-18 are essential for IFN-γ-dependent restriction of type A Francisella tularensis infection.

Authors:  Jerod A Skyberg; Carolyn A Lacey
Journal:  J Leukoc Biol       Date:  2017-09-26       Impact factor: 4.962

Review 2.  New insights into the regulation of neutrophil NADPH oxidase activity in the phagosome: a focus on the role of lipid and Ca(2+) signaling.

Authors:  Sabrina Bréchard; Sébastien Plançon; Eric J Tschirhart
Journal:  Antioxid Redox Signal       Date:  2012-09-18       Impact factor: 8.401

3.  Innate immunity against Granulibacter bethesdensis, an emerging gram-negative bacterial pathogen.

Authors:  Kol A Zarember; Kimberly R Marshall-Batty; Anna R Cruz; Jessica Chu; Michael E Fenster; Adam R Shoffner; Larissa S Rogge; Adeline R Whitney; Meggan Czapiga; Helen H Song; Pamela A Shaw; Kunio Nagashima; Harry L Malech; Frank R DeLeo; Steven M Holland; John I Gallin; David E Greenberg
Journal:  Infect Immun       Date:  2011-12-19       Impact factor: 3.441

Review 4.  Mechanisms of Francisella tularensis intracellular pathogenesis.

Authors:  Jean Celli; Thomas C Zahrt
Journal:  Cold Spring Harb Perspect Med       Date:  2013-04-01       Impact factor: 6.915

5.  EmrA1 membrane fusion protein of Francisella tularensis LVS is required for resistance to oxidative stress, intramacrophage survival and virulence in mice.

Authors:  Zhuo Ma; Sukalyani Banik; Harshita Rane; Vanessa T Mora; Seham M Rabadi; Christopher R Doyle; David G Thanassi; Chandra Shekhar Bakshi; Meenakshi Malik
Journal:  Mol Microbiol       Date:  2014-02-08       Impact factor: 3.501

6.  Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.

Authors:  Joshua D Hall; Matthew D Woolard; Bronwyn M Gunn; Robin R Craven; Sharon Taft-Benz; Jeffrey A Frelinger; Thomas H Kawula
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

7.  The type I NADH dehydrogenase of Mycobacterium tuberculosis counters phagosomal NOX2 activity to inhibit TNF-alpha-mediated host cell apoptosis.

Authors:  Jessica L Miller; Kamalakannan Velmurugan; Mark J Cowan; Volker Briken
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

8.  Filifactor alocis modulates human neutrophil antimicrobial functional responses.

Authors:  Jacob S Edmisson; Shifu Tian; Cortney L Armstrong; Aruna Vashishta; Christopher K Klaes; Irina Miralda; Emeri Jimenez-Flores; Junyi Le; Qian Wang; Richard J Lamont; Silvia M Uriarte
Journal:  Cell Microbiol       Date:  2018-02-12       Impact factor: 3.715

9.  Francisella tularensis induces extensive caspase-3 activation and apoptotic cell death in the tissues of infected mice.

Authors:  Jason R Wickstrum; Sirosh M Bokhari; Jeffrey L Fischer; David M Pinson; Hung-Wen Yeh; Rebecca T Horvat; Michael J Parmely
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

10.  Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.

Authors:  Jerod A Skyberg; Maryclare F Rollins; Joshua W Samuel; Marjorie D Sutherland; John T Belisle; David W Pascual
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.